When your patients need another option for treating MS relapse, Acthar is an alternative that speeds relief.3
Acthar is a proprietary, prolonged-release formulation of the naturally occurring adrenocorticotropic hormone (ACTH) and other peptides.3 It has been used to treat patients with MS relapse—speeding relief from the relapse—since its FDA approval for that indication in 1978.3,32
In a clinical study at week 1, 70% of Acthar-treated patients experienced improvement in their overall condition compared to 49% of placebo-treated patients, a trend that continued throughout the study period.2*†
In the same study, 65% of Acthar-treated patients showed improvement of greater than or equal to 1 DSS step at week 4 compared to 48% of placebo-treated patients.2*§
*In a randomized, double-blind, placebo-controlled study, patients with acute MS relapses were given ACTH gel (n=103) or placebo gel (n=94) intramuscularly 40 units twice daily for 7 days, 20 units twice daily for 4 days, and 20 units daily for 3 days. Neurologic evaluations were performed within 24 hours before treatment, on days 7 and 14 during treatment, and on days 7 and 14 after treatment. Clinical assessments included: 1) an overall clinical assessment of neurologic impairment and change, 2) a detailed Standard Neurological Examination, 3) the Disability Status Scale, 4) tabulation of subjective symptoms by type, severity, and duration, and 5) a battery of quantitative tests administered by physical therapists.
†The estimate in overall condition is a subjective measure designed to evaluate change in the patient’s condition as a whole, regardless of the nature or extent of the specific neurologic deficits that may have changed. Clinicians used their experience to judge whether a patient’s pretreatment condition was improved, worse, or the same as the last examination. Estimate of overall condition was at each weekly exam vs pretreatment exam according to treatment (cumulative frequency percentages). The methods of calculating significance were not provided and cannot be verified.
‡The authors of this study determined the significance of specified outcomes; however, the methods of calculating significance were not provided and cannot be verified.
§The DSS is a scale of 10 steps, from 0 to 10, on which increasing numbers indicate increasing severity of disease. Clinically, the scale measures up to 9, and 10 represents death. One step on the DSS is defined as a change in numerical grade from one examination to the next. Today, the DSS has generally been replaced by the EDSS to assess the severity of disease.23
The support you expect
Learn how specialists from the Acthar Support & Access Program (A.S.A.P.) provide reimbursement support to help your office and your patients coordinate approvals, injection training, and payment.
H.P. Acthar® Gel (repository corticotropin injection) is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease.
Warning and Precautions
Please see full Prescribing Information for additional Important Safety Information.